Growing human mini-livers to test for drug induced liver injury
Transition Grant
Growing human mini-livers to test for drug induced liver injury
Professor Ken Linton
Queen Mary University London
Professor Ken Linton at Queen Mary University London is using stem cells to grow human “mini-livers” to test and identify drugs that may cause drug induced liver injury (DILI).
Animals to be replaced
Guinea pigs
Mice
Rats
Rabbits
Drug induced liver injury (DILI)
The liver is an important organ that is involved in many bodily functions including food digestion and the breakdown (metabolism) of drugs into inactive forms. Once the liver has processed a drug, it is usually removed from the body through the digestive tract. However, sometimes drugs can remain active or be changed into a more harmful form, which can make it harder for the liver to remove.
If a drug is taken repeatedly, harmful toxins can build up in the liver and cause a condition known as drug induced liver injury (DILI). All drugs have the potential to cause DILI, even commonplace painkillers like paracetamol and antibiotics, but most symptoms are mild and many people fully recover once they stop taking the drug that caused it. Some patients can however become very unwell and develop other serious health problems, leading to a risk of death. Around 9.4% of DILI patients will die or need a liver transplant within 2 years following diagnosis.Â
We don’t really know who is at high risk for developing DILI or who will be affected badly by it, although it is more common in older people, those with pre-existing liver problems, and people with a higher body mass index (BMI). It is also thought that people with a fatty liver, or those who have non-alcoholic fatty liver disease (NAFLD), could be more sensitive to the toxic effects of some drugs and so may be at a higher risk, but this has not been well explored.Â
Liver transporter proteins – miniature conveyor belts
The liver is the main organ responsible for the processing (metabolism) of drugs, turning them into forms that are easier to use and clear from the body. To help with this process, the liver makes a fluid called bile which helps break down fats during digestion and carries waste products out of the liver into the digestive tract.
Special proteins known as transporters act as miniature conveyor belts to move the bile and processed drugs out of the liver into the gut, where they are safety removed from the body. However, sometimes drugs mistakenly target these transporters and stop them from being able to carry out their normal functions, resulting in a toxic build up of drug particles, causing damage to the liver in the form of DILI.
Animals in drug development
Although drugs are tested in two species of animals (usually mice or rats, and a second species such as dogs) before they are approved for use in humans, DILI is still a common problem which can result in serious problems for patients and even death.Â
This is because there are important differences in how animals process drugs compared to humans, but also in the chemical makeup of human and animal bile fluid and in its production. These differences mean that drugs that don’t cause any harmful effects during animal experiments can sometimes fail to accurately predict liver toxicity in humans, with dangerous consequences for patients. Despite this, 153,736 animals were used in 2023 for the regulatory testing of new drugs in the UK, including 97,082 mice, 42,788 rats, 2,275 beagles and 1,732 monkeys.
A better model of toxicity
Human liver cell models are widely used in research into liver diseases, but they can sometimes be difficult to use as when liver cells are grown for long periods of time they can lose or undergo changes in their unique characteristics, including their ability to make bile. This could make the results less similar to what happens in the body, making it more difficult to translate the results into breakthroughs for patients.
To overcome this problem, Professor Ken Linton at Queen Mary University London has developed a new way to grow liver cells from human stem cells (special cells which can be turned into any other cell type in the body). These cells are able to keep their unique characteristics, and most importantly, keep their bile-making abilities when grown in the lab for long periods of time. This model will be used to test drug safety, identifying drugs which could be most likely to cause DILI, and their effects on the liver’s transporter proteins will also be assessed.
Professor Linton is currently growing these liver cells using an animal-derived product called Matrigel, which is made using mice. During this project, he will trial animal-free alternatives to Matrigel to make the model completely animal-free.
Impact and future goalsÂ
Millions of animals are used each year worldwide for the safety testing of drugs and other substances. If scaled up, Professor Linton’s innovative animal-free methods could provide a limitless supply of human liver cells to replace animals in these experiments, while gaining human-relevant results. This could ultimately lead to safer and more effective treatments for patients, while also saving the lives of laboratory animals.
Over the course of the project, Professor Linton will train students and early career researchers to use these animal-free techniques, and will publish his methods to help other scientists to replace animals in their work.

Drugs are tested on animals including dogs before they are given to patients, but animals can’t predict which drugs are likely to cause drug induced liver injury (DILI) in humans.

Even commonplace drugs like paracetamol and antibiotics can cause drug induced liver injury, leading to serious side effects in older people or those with pre-existing liver conditions.

Professor Linton’s innovative methods could create an unlimited number of liver cells to help replace animal experiments and improve drug safety.
